- Home
- RSF vs CNTX Comparison
RSF vs CNTX Comparison
Compare RSF & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | CNTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 116.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RSF | CNTX |
|---|---|---|
| Price | $14.51 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 11.8K | ★ 713.8K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.81 | $0.49 |
| 52 Week High | $16.23 | $1.55 |
Technical Indicators
Market Signals| Indicator | RSF | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 48.03 |
| Support Level | $14.40 | $1.07 |
| Resistance Level | $14.55 | $1.34 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.03 | 28.71 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.